Overview
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Lobbying Costs
None declared
Financial year: Jan 2021 - Dec 2021
Lobbyists (Full time equivalent)
0.3 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
8
Lobbying Costs over the years
-
Info
European Organisation for Research and Treatment of Cancer (EORTC)
EU Transparency Register
70539554035-46 First registered on 20 Aug 2010
Goals / Remit
The European Organisation for Research and Treatment of Cancer (EORTC) has delivered investigator driven, changing practice clinical trials since 1962. Its mission is to improve survival and quality of life of cancer patients. The EORTC is a not-for-profit independent organisation performing multidisciplinary clinical research activities across tumor types. The EORTC aims to improve the standard of cancer treatment through the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. EORTC’s activities involve on a voluntary basis more than 3000 medical doctors and scientists from some 800 university hospitals in 35 countries. EORTC clinical trials are involving several thousands of cancer patients on a yearly basis. The EORTC operates on an independent basis, and in this capacity is able to work in partnership with the pharmaceutical industry in evaluating innovative molecules.
Main EU files targeted
- Regulation on clinical trials on medicinal products for human use.
-Regulation on Health Technology Assessment.
-Early access to medicines: PRIME, accelerated assessment, conditional market authorization.
- Good Clinical Practice implementation.
- General Data Protection Regulation.
- Regulation of the European Parliament and of the Council on in vitro diagnostic medical devices.
- Euratom and radioprotection.
- EU Beating Cancer plan.
- EU Cancer Mission.
- EU Roadmap for a pharmaceutical strategy for Europe.
- Pharmaceutical strategy for Europe
- EU Partnership for Health Innovation.
- European Health Data SpaceAddress
Head Office
avenue Mounier, 83
Brussels 1200
BELGIUMEU Office
avenue Mounier, 83
Brussels 1200
BELGIUMWebsite
-
People
Total lobbyists declared
3
Employment time Lobbyists 10% 3 Lobbyists (Full time equivalent)
0.3
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
European Cancer Organisation
European Forum for Good Clinical Practice
European Alliance for Personnalised Medicine
European Association for NeuroOncology
European Association of Urology
European School of Oncology
European Association of Urology
American Association for Cancer Research
European Society for Therapeutic Radiology and Oncology
European Society for Medical Oncology
American Society for Therapeutic Radiology and Oncology
International Society of Geriatric Oncology
International Society of Pediatric Oncology
International Union Against Cancer
International Network for Cancer Research and Treatment
Organisation of European Cancer Institutes
European Oncology Nursing Society
European Society of Pathology
European Society of RadiologyMember organisations
None declared
-
Financial Data
Interests represented
Does not represent commercial interests
Closed financial year
Jan 2021 - Dec 2021
Lobbying costs for closed financial year
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Total organisational budget in closed year
52,000€
Major funding types in closed year
Public financing, Other, Grants
Major contributions in closed year
Type Name Amount Contribution Merck Sharp & Dohme 3,988,854€ Contribution Sanofi-Aventis 4,235,450€ Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
Cancer
Other activities
- International investigator-driven clinical trials
- Funding independent clinical research.
- Human biological material for use in research
- Secondary use of clinical data.
- Precision Medicine
- Real world data
- Treatment optimization.
- Access to treatment, quality of life.
- Evidence generation for clinical decision.
Keywords: Health, cancer, clinical and translational research, complex clinical trial, study sponsorship, medicine, drugs, surgery, radiotherapy, chemotherapy, imaging, laboratory, patient, pharmacovigilance, quality insurance, biostatistics, biobank, regulatory, quality of life, funding, sequencing, molecular screening platform.Meetings
Meetings
8 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.
-
Date 11 Mar 2022 Location Brussels, virtual Subject Discussion on Europe's Beating Cancer Plan and breast cancer Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Tove Ernst (Cabinet member)
-
Date 24 Feb 2021 Location Brussels - virtual meeting Subject Exchange of views on Europe’s Beating Cancer Plan, the EU Pharmaceutical Strategy and the availability of medicines. Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 03 Nov 2020 Location Brussels - virtual call Subject Exchange of views on Europe’s Beating Cancer Plan Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Tove Ernst (Cabinet member)
-
Date 19 Feb 2020 Location Brussels Subject challenges of documenting robust evidence for the use of cancer treatments Attending - Anne Bucher (Director-General)
-
Date 05 Feb 2020 Location Brussels Subject Discussion on Cancer and Europe's Beating Cancer Plan Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
Other Lobbyists -
Date 03 May 2018 Location Brussels Subject HTA Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)
- Vytenis Andriukaitis (Commissioner)
Other Lobbyists - The European Association of Hospital Pharmacists
- European Public Health Association
- Phamaceutical Group of the European Union
- European Forum for Primary Care
- European Union of General Practitioners / Family Physicians (Union Européenne des Médecins Omnipraticiens / Médecins de Famille)
- European Society for Medical Oncology (ESMO)
- Standing Committee of European Doctors
- European Hospital and Healthcare Federation
- European Society of Cardiology
-
Date 16 Apr 2018 Location Brussels Subject Discussion Cancer Research Attending - Xavier Prats Monné (Director-General)
-
Date 05 May 2017 Location Brussels Subject Clinical research Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)